Coronavirus

The ideal vaccine should be effective with 1 or 2 doses, protect risk groups, reduce community transmission, generate long-lasting immunity, and be capable of being produced on a large scale in a short time.

An autumn full of uncertainties is coming, it is difficult for us to imagine the future post-COVID-19, and we more easily resort to feeding nostalgia. What can we do to ease this sadness?

A new review published in 'Frontiers in Public Health' suggests that SARS-CoV-2, which causes COVID-19, will likely follow the lead of other viruses that cause common colds, becoming seasonal in countries with temperate climates. Of course, it will only happen when we have developed herd immunity.

An international macro-study suggests that the existence of a segment of DNA inherited from Neanderthals puts their carriers at up to three times the risk of developing serious complications from COVID-19.

This is the first compelling evidence, according to a study published in Frontiers in Microbiology, of organisms that use viruses for food.

At the beginning of the pandemic, there were concerns that certain medications used to control high blood pressure could be harmful to COVID-19 sufferers.

The predominant mode of transmission for COVID-19 is respiratory. The problem is that the label 'respiratory' has a notable controversy surrounding it.

The main reason is that lifelong immunity to coronaviruses is unlikely. There is usually reinfection every three to four years.